Pharmacovigilance Risk Assessment Committee (PRAC): 4 - 7 May 2026, European Medicines Agency, Amsterdam, the Netherlands, from 4 May 2026 to 7 May 2026

Submitted by Anonymous (not verified) on 4 May 2026 - 15:53

Pharmacovigilance Risk Assessment Committee (PRAC): 4 - 7 May 2026, European Medicines Agency, Amsterdam, the Netherlands, from 4 May 2026 to 7 May 2026

Product Management Service (PMS) information day 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 9 June 2026, 08:45 (CEST) to 9 June 2026, 17:00 (CEST)

Submitted by Anonymous (not verified) on 4 May 2026 - 15:47

Product Management Service (PMS) information day 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 9 June 2026, 08:45 (CEST) to 9 June 2026, 17:00 (CEST)

Human medicines European public assessment report (EPAR): Leqembi, lecanemab, Date of authorisation: 15/04/2025, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 4 May 2026 - 15:19

Human medicines European public assessment report (EPAR): Leqembi, lecanemab, Date of authorisation: 15/04/2025, Revision: 3, Status: Authorised

FDIME Announcement: A Grant for Research on AI use in Internal Medicine

Submitted by Catalina on 4 May 2026 - 13:58

The Foundation for the Development of Internal Medicine in Europe (FDIME) announces the of a new grant for EFIM Young Internists. 

The funding is intended for research projects dedicated to AI applications in Internal Medicine.

A 15,000 Euros grant will be awarded.
Young internists (up to the age of 40 years) from EFIM member countries are the target audience. 
The eligibility criteria must be met as stated in the Announcements.

Applicants are required to submit their own Research Project proposal.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness